BA
AXSM icon

Bridgewater Associates’s Axsome Therapeutics AXSM Stock Holding History

Bridgewater Associates’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.63M Buy
56,951
+9,507
+20% +$1.64M 0.04% 273
2025
Q4 		$8.67M Buy
+47,444
New +$6.62M 0.03% 392
2025
Q3 		– Sell
-107,292
Closed -$11.2M – 1019
2025
Q2 		$11.2M Buy
107,292
+64,467
+151% +$6.83M 0.05% 240
2025
Q1 		$4.99M Buy
+42,825
New +$4.88M 0.02% 356

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgewater Associates's AXSM Position: Q1 2026 in Review

Bridgewater Associates increased its Axsome Therapeutics (AXSM) stake by 20% in Q1 2026, buying an estimated $1.64M and bringing the position to 56,951 shares worth $9.63M. The position accounts for 0.04% of the portfolio, ranked #273.

Bridgewater Associates first reported a position in AXSM in Q1 2025 and has held it in 4 quarters since. The position peaked at $11.2M in Q2 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Bridgewater Associates held 56,951 shares of Axsome Therapeutics worth $9.63M as of Q1 2026.
  • Bridgewater Associates bought 9,507 Axsome Therapeutics shares in Q1 2026, an estimated $1.64M.
  • Axsome Therapeutics made up 0.04% of Bridgewater Associates's portfolio in Q1 2026, its #273 holding.
  • Bridgewater Associates first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • Bridgewater Associates's Axsome Therapeutics position peaked at $11.2M in Q2 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.